Trial reportRespiration; international review of thoracic diseases
Safety and Dose Study of Targeted Lung Denervation in Moderate/Severe COPD Patients.
Trial report in Respiration; international review of thoracic diseases. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 38 citations in OpenAlex.
- Randomized Sham-controlled Trial of Targeted Lung Denervation in Patients with Chronic Obstructive Pulmonary Disease (AIRFLOW-3).American journal of respiratory and critical care medicine · 2025Trial
- Two-Year Outcomes for the Double-Blind, Randomized, Sham-Controlled Study of Targeted Lung Denervation in Patients with Moderate to Severe COPD: AIRFLOW-2.International journal of chronic obstructive pulmonary disease · 2020Trial
- Safety and Adverse Events after Targeted Lung Denervation for Symptomatic Moderate to Severe Chronic Obstructive Pulmonary Disease (AIRFLOW). A Multicenter Randomized Controlled Clinical Trial.American journal of respiratory and critical care medicine · 2019Trial
- The Rise and Fall of Interventional Pulmonology Procedures: Lessons in Innovation, Evidence, and Abandonment.Diagnostics (Basel, Switzerland) · 2026Review
- A novel targeted lung denervation multi-polar radiofrequency ablation system for moderate to severe COPD patients: a translational study.Respiratory research · 2026Article
- Autonomic nervous system dysfunction in chronic obstructive pulmonary disease: mechanistic insights and therapeutic implications.Annals of medicine · 2025Review
- Interventional pulmonology for chronic inflammatory airway diseases.Chinese medical journal pulmonary and critical care medicine · 2024Review
- Bronchoscopic Management of COPD and Advances in Therapy.Life (Basel, Switzerland) · 2023Review
- Which Endoscopic Procedure to Use and in What Patient? Valves, Coils, Foam, and Heat in COPD and Asthma.Pulmonary therapy · 2023Review
- Modern Bronchoscopic Treatment Options for Patients with Chronic Bronchitis.Journal of clinical medicine · 2023Article
- Bronchoscopic Targeted Lung Denervation in Patients with Severe Asthma: Preliminary Findings.Respiration; international review of thoracic diseases · 2022Article
- New bronchoscopic treatment modalities for patients with chronic bronchitis.European respiratory review : an official journal of the European Respiratory Society · 2021Review
- Bronchoscopic management of asthma, COPD and emphysema.European respiratory review : an official journal of the European Respiratory Society · 2021Article
- Chronic obstructive pulmonary disease phenotypes: imprint on pharmacological and non-pharmacological therapy.Annals of translational medicine · 2020Review
- Targeted lung denervation in sheep: durability of denervation and long-term histologic effects on bronchial wall and peribronchial structures.Respiratory research · 2020Article
- Design for a multicenter, randomized, sham-controlled study to evaluate safety and efficacy after treatment with the Nuvaira® lung denervation system in subjects with chronic obstructive pulmonary disease (AIRFLOW-3).BMC pulmonary medicine · 2020Article
- Respiratory Sinus Arrhythmia Attenuation via Targeted Lung Denervation in Sheep and Humans.Respiration; international review of thoracic diseasesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 8 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleTargeted lung denervation (TLD) is a novel bronchoscopic treatment for the disruption of parasympathetic innervation of the lungs.
objectivesTo assess safety, feasibility, and dosing of TLD in patients with moderate to severe COPD using a novel device design.
methodsThirty patients with COPD (forced expiratory volume in 1 s 30-60%) were 1:1 randomized in a double-blinded fashion to receive TLD with either 29 or 32 W. Primary endpoint was the rate of TLD-associated adverse airway effects that required treatment through 3 months. Assessments of lung function, quality of life, dyspnea, and exercise capacity were performed at baseline and 1-year follow-up. An additional 16 patients were enrolled in an open-label confirmation phase study to confirm safety improvements after procedural enhancements following gastrointestinal adverse events during the randomized part of the trial.
resultsProcedural success, defined as device success without an in-hospital serious adverse event, was 96.7% (29/30). The rate of TLD-associated adverse airway effects requiring intervention was 3/15 in the 32 W versus 1/15 in the 29 W group, p = 0.6. Five patients early in the randomized phase experienced serious gastric events. The study was stopped and procedural changes made that reduced both gastrointestinal and airway events in the subsequent phase of the randomized trial and follow-up confirmation study. Improvements in lung function and quality of life were observed compared to baseline values for both doses but were not statistically different.
conclusionsThe results demonstrate acceptable safety and feasibility of TLD in patients with COPD, with improvements in adverse event rates after procedural enhancements.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.